Tyzine

Quick links to important sections

Tyzine

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tyzine

Quick Facts

Property Description
Active ingredient Tetryzoline hydrochloride (Tetrahydrozoline)
Form Aqueous Solution (Nasal or Ophthalmic)
Pharmacological class Sympathomimetic Amine; Vasoconstrictor
General use Symptomatic relief of congestion and redness
Origin Synthetic (Imidazole derivative)

What Type of Medicine is Tyzine (Tetryzoline)?

Tyzine is a medicinal preparation classified as a topical decongestant and a sympathomimetic amine, primarily intended to relieve localized congestion. The active ingredient is Tetryzoline hydrochloride, also identified as Tetrahydrozoline, a synthetic compound derived from the Imidazole derivative family. Pharmacologically, it operates as a selective alpha1-adrenergic agonist, meaning the medicine is designed to stimulate specific receptors on blood vessel walls, mimicking the effects of the body's natural adrenergic compounds. This compound is clinically recognized for its capacity to reduce vascular swelling.

Tetryzoline Forms, Application, and General Purpose

Tetryzoline is specifically formulated as an aqueous solution intended strictly for topical administration as an Over-the-Counter (OTC) product for temporary symptom relief. It is typically available as a single-ingredient product in two main dosage forms: a nasal solution (spray) and an ophthalmic solution (eye drops). The preparation is generally used to provide symptomatic relief for the temporary physical effects of congestion or redness, easing discomfort often associated with a blocked nose due to a cold. It achieves this general purpose by inducing vasoconstriction, or the temporary tightening of localized small blood vessels, which physically reduces the swelling and redness in the applied membranes. This targeted action allows the medicine to quickly decrease the volume of the congested tissue, providing prompt relief.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Tyzine?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Tetryzoline (Tyzine) around potential local effects at the application site and the risk of systemic sympathomimetic reactions.


Adverse Reactions and Classifications

Adverse reactions are classified by official regulatory bodies, such as the FDA and EMA, into categories of frequency and affected organ systems.

Category Documented Effects
Common Effects Mild stinging or burning sensation, temporary blurred vision, watery eyes, and pupil dilation (mydriasis) [Eye Disorders].
Systemic Effects Nervousness, headache, palpitation, tachycardia (fast heart rate), hypertension (high blood pressure), and nausea [Nervous System, Cardiac, and Vascular Disorders].

Safety Considerations

The medicine's safety profile includes important notes regarding exposure and specific patient populations.

  • Overuse and Rebound: Prolonged or excessive use is associated with rebound phenomena. This includes rebound hyperemia (increased eye redness) with ophthalmic use and rhinitis medicamentosa (rebound nasal congestion) with nasal preparations.
  • Serious Toxicity Risk: Accidental ingestion, particularly by young children, is explicitly documented as a cause of severe toxicity. This can lead to serious adverse events requiring hospitalization, including coma, marked respiratory depression, and severe bradycardia (decreased heart rate).
  • Safety Restrictions: Due to its vasoconstrictive properties, the medicine requires caution in patients with certain pre-existing conditions, such as narrow-angle glaucoma, severe hypertension, coronary artery disease, or diabetes mellitus. It is contraindicated in patients using Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing such treatment.
  • Pediatric Use: Safety and efficacy are not established for ophthalmic use in children under six years of age.

This information is derived from government regulatory sources and is not intended as clinical advice.

Overdose and Emergency Response

Overdose and when to seek help

The Tetryzoline overdose profile is classified by regulatory authorities as a medical emergency due to the potential for life-threatening systemic toxicity following accidental ingestion, particularly in children.

Documented Overdose Manifestations

System Documented Signs and Symptoms
Central Nervous System Profound CNS depression, leading to coma, stupor, sedation, lethargy, severe headache.
Cardiovascular Severe fluctuations, including bradycardia (decreased heart rate), hypotension (low blood pressure), transient hypertension, and circulatory shock.
General/Other Respiratory depression, hypothermia, drooling, nausea, and vomiting.

Required Emergency Actions

The regulatory labeling explicitly mandates that users seek emergency medical care immediately following accidental ingestion of the topical solution. Due to the high risk of serious adverse events, including CNS and cardiac collapse, the Poison Help Line must be contacted right away.

Overdose Management Profile

Accidental ingestion leading to systemic effects is most often documented in children 5 years of age and younger. Management is focused on symptomatic and supportive treatment, including close monitoring of vital signs (e.g., ECG) and supportive procedures like the use of intravenous fluids or activated charcoal, as no specific antidote is known.

Therapeutic Uses of Tyzine

What Tyzine Treats: Main Uses and Benefits

Tetryzoline is commonly used to provide localized support for symptomatic relief across two primary domains: ocular hyperemia (eye redness) and nasal congestion. This medication is applicable in conditions characterized by periods of heightened symptoms that interfere with daily comfort. The therapeutic use is focused on managing symptoms that may appear suddenly or fluctuate, such as minor eye irritation, burning, stuffiness, and blockage of the nasal passages.

This medicine is generally applied in contexts where short-term symptomatic assistance is needed, often during acute, episodic congestion associated with a common cold or minor upper respiratory tract sensitivities, as well as irritation caused by temporary factors like dust, wind, or swimming. The medicine is relevant for easing symptoms that are disruptive, helping patients cope more steadily with symptom fluctuations. By easing the overall symptom burden, the medication contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms become more noticeable.


Quick Fact: Relief for Acute Symptoms
Primary Ocular Use Contributes to easing visible redness and discomfort from minor environmental irritants.
Primary Nasal Use Helps manage stuffiness and blockage due to acute cold or allergic response.
Benefit Focus Supportive relief for temporary, episodic symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Tyzine (Tetryzoline) is defined by official regulatory documents through a clear set of contraindications and restrictions related to age and pre-existing medical conditions.

Contraindications and Prohibited Populations

Use of Tetryzoline is absolutely contraindicated in specific patient groups, including individuals with narrow-angle glaucoma and those with a documented hypersensitivity to the active ingredient or any excipients. Furthermore, the use of Tetryzoline is explicitly contraindicated in children under two years old due to the risk of serious systemic effects from ingestion or high absorption. The medicine must not be used by patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuation.

Age-Related and Condition-Based Restrictions

Use requires professional consultation and caution in populations with certain comorbidities, such as hypertension, severe cardiovascular disease, diabetes mellitus, and hyperthyroidism. For the pediatric population, safety and efficacy are not established in children under six years old for ophthalmic formulations. For pregnant or breastfeeding women, the regulatory labels state to ask a health professional before use, and use is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Tetryzoline hydrochloride (Tyzine), primarily the FDA-published Over-the-Counter (OTC) Drug Facts Labels, defines a highly focused interaction profile. This profile is notable for the non-documentation of specific, named interactions across most medicinal product categories and pharmacokinetic pathways.

Pharmacodynamic Interactions and Restrictions

One critical interaction pattern is identified due to the sympathomimetic properties of Tetryzoline and the potential for systemic absorption: co-administration with Monoamine Oxidase Inhibitors (MAOIs). This medicinal product class, which includes substances such as isocarboxazid, phenelzine, or tranylcypromine, may result in a severe increase in blood pressure.

The official labeling establishes a mandatory interaction-related restriction: Tetryzoline must not be used if MAOIs have been taken within the previous 14 days. This prohibition serves as the sole formally documented combination restriction in the regulatory profile.

Other Interaction Categories

For all other interaction categories, including pharmacokinetic enzyme systems (e.g., CYP enzymes) and drug transporters, the official regulatory documents provide no explicit statements or warnings. Consequently, no timing-based separation requirements or specific restrictions concerning food, alcohol, or herbal products are documented in the official labeling. The resulting structure confirms that outside of the MAOI restriction, no mandatory combination constraints are specified.

Mechanism of Action

Selective Activation of Vascular alpha1-Adrenergic Receptors

Tetryzoline acts as a selective agonist on post-synaptic alpha1-adrenergic receptors (alpha1-ARs), which are the biological targets primarily found on the smooth muscle cells of small blood vessels in mucosal tissues. By mimicking the body's natural sympathetic signaling, the compound initiates a molecular cascade that alters local vascular tone.


The Vasoconstriction Cascade and Tissue Volume Reduction

This receptor activation triggers the G q protein pathway, leading to a surge of intracellular calcium ions ( Ca^2+) that causes the vascular smooth muscle to contract (vasoconstriction). This direct mechanical tightening of the vessels reduces localized blood flow and tissue engorgement, resulting in the physical displacement of fluid volume from the targeted tissue bed.


Mechanism Constraint: Receptor Desensitization

The capacity of this vasoconstrictive mechanism is constrained by the biological process of receptor desensitization (tachyphylaxis). Persistent exposure to Tetryzoline can cause the alpha1-ARs to become less responsive, leading to a functional weakening of the mechanism that may result in a paradoxical rebound vascular engorgement when the drug's effect dissipates.

Dosage and Administration Information

Official Administration Guidelines for Tetryzoline

The use of Tetryzoline (Tyzine) follows specific parameters concerning its route, dosage limits, and duration of application.

Administration Scope Standard Parameters
Route of Administration Tetryzoline is intended exclusively for topical use, administered as either an ophthalmic solution (eye drops) or a nasal solution (drops or spray).
Standard Dosing Schedule The standard adult application for the ophthalmic form involves instilling 1 to 2 drops into the affected eye(s) per administration. Nasal dosing regimens vary by specific formulation and concentration.
Frequency and Timing The medicine is used on an as-needed basis, with a maximum limit of up to 4 times daily in the affected area(s).
Course Duration Use is designated for short-term relief only. Guidelines indicate that the medicine should be discontinued if the condition worsens or persists for more than 72 hours (three days).
Age-Group Rules Administration to children under 6 years of age occurs following the determination of a healthcare professional. Children 6 years and older typically follow the standard adult dosing regimen.

Procedural Constraints

Key procedural steps are established for proper administration. For ophthalmic use, soft contact lenses must be removed before the application of the drops. Additionally, the tip of the container must not touch any surface during the process to prevent product contamination and maintain solution integrity. These guidelines establish the framework for the appropriate, short-term application of Tetryzoline.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research evaluated measurements related to joint function in patients with chronic inflammatory arthritis. Clinical trials included participants with varying disease activity levels who had not adequately responded to prior treatments.

  • Phase 1 & 2: Early studies examined findings related to pain and morning stiffness. These trials focused primarily on safety, dosage, and how the drug behaved in the body.
  • Phase 3: Pivotal trials compared the investigational drug to placebo or an active comparator. Studies assessed whether the combination of the drug with standard therapy affected remission rates. Long-term use in adults was evaluated in clinical studies.

Mechanism of Action Studies

Research examined the drug's interaction with specific signaling pathways. Research explored potential biological effects, including findings related to inflammation. Studies assessed inflammation levels over time.


Patient-Reported Outcomes (PROs)

A range of studies assessed patient-reported outcomes to understand the potential impact on daily living. These outcomes included evaluations of fatigue, physical function, and overall quality of life. Findings were mixed; some studies reported changes in physical function scores.


Comparative Effectiveness Research

Studies compared findings of this treatment with existing biologics. Research has explored whether the drug's route of administration (oral) may affect patient adherence compared to treatments requiring injection. It is not yet clear whether one treatment provides better long-term outcomes than another.


Specific Disease Subsets

Studies explored the drug in patient populations with both early- and late-stage disease. Research evaluated the drug in patients who had failed previous treatments.


Safety and Tolerability

Some reported side effects were observed. Studies included monitoring of liver enzymes, and researchers assessed the incidence of infections. Individuals may wish to consult their doctor for personalized information about the study findings.

Key Studies & References

  1. American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis (Source for context on treatment pathways and comparative efficacy)
  2. Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy (Comprehensive review covering mechanism and clinical trials)

Frequently Asked Questions (FAQ)

Common questions about Tyzine (FAQ)


Q: Can Tyzine be taken by children?

Official regulatory documents state that the use of Tetryzoline in children is governed by specific age restrictions. For children aged 6 years and older, the use is generally aligned with the standard adult use conditions. Use in children under 6 years is subject to professional determination prior to administration.


Q: Is Tyzine safe to take if I am pregnant?

According to the official product information, the FDA pregnancy category for Tetryzoline has not been formally assigned. Official labeling states that a health professional should be consulted before use if one is pregnant or breastfeeding.


Q: What do the research studies say about Tyzine’s long-term use?

Tetryzoline is officially designated for short-term relief only. Official regulatory labeling specifies that the medicine is to be discontinued if the condition persists for more than 72 hours (three days). The medicine’s mechanism of action is limited by the potential for receptor desensitization, a process where persistent exposure can cause the drug to become less responsive over time.


Q: Is Tyzine safe for people with a history of heart issues?

Official regulatory documents indicate that due to Tetryzoline's nature as a vasoconstrictor, it requires caution in patients with certain pre-existing conditions. These include severe cardiovascular disease and hypertension (high blood pressure). The official labeling outlines the required restrictions and cautions for use.


Q: Is Tyzine a type of antibiotic?

No, Tetryzoline is not classified as an antibiotic. According to the official product information, it belongs to the pharmacological class of a sympathomimetic amine and functions as a topical decongestant. This means it works by targeting specific receptors on blood vessels to relieve congestion.


Q: How long does the effect of Tyzine last?

Studies and official product information indicate that the mean serum half-life of Tetryzoline following therapeutic ocular use is approximately 6 hours. The regulatory guidelines for application frequency are set at a maximum of up to four times daily.


Q: Can Tyzine make you feel sleepy or tired?

Drowsiness or sleepiness is generally not listed as a common side effect of therapeutic use in official documentation. However, regulatory safety guides emphasize that these effects, along with an altered mental state, are potential symptoms of overdose or accidental ingestion, particularly in young children.


Q: Will Tyzine interact with my blood pressure medicine?

The most critical restriction documented in official labeling is the prohibition against co-administration with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe blood pressure increase. For other types of blood pressure medication, regulatory-based interaction checking resources indicate that major and moderate potential interactions may exist with certain classes.


Q: Why do some people say they have trouble sleeping on Tyzine?

Regulatory documents list nervousness and headache as documented systemic side effects. These types of effects, which relate to the central nervous system and circulation, may potentially contribute to a user's difficulties with sleep, although insomnia itself is not listed as a common adverse reaction.


Q: Is Tyzine used for anything else besides its main purpose?

The approved uses listed in official regulatory documents are strictly limited to the temporary relief of discomfort, redness, and congestion of the eye or nasal/nasopharyngeal mucosa. The medicine is not officially indicated for any other medical purpose.


Q: Is it normal to have a slight headache when starting Tyzine?

Official documents list headache as a documented systemic effect that may occur with the medicine’s use. This type of reaction is defined in the product's safety profile derived from regulatory sources.


Q: Does Tyzine have a warning about driving or operating machinery?

Official documentation does not always contain an explicit warning about driving or operating machinery. However, regulatory documents list temporary blurred vision as a common side effect and altered mental state as a symptom of toxicity, which indicates a need for awareness regarding potential temporary impairment.


Q: Can I take ibuprofen or pain relievers with Tyzine?

The official regulatory label does not provide specific statements regarding common nonprescription pain relievers. However, regulatory-based interaction checking resources indicate there are potential moderate interactions with some common pain relievers, such as Acetaminophen or Naproxen.


Q: Are there any specific lifestyle changes recommended while on Tyzine?

The official administration procedure for ophthalmic use specifies that soft contact lenses are to be removed before the drops are administered. Other general lifestyle recommendations are not documented in the product’s official regulatory information.


Q: Is Tyzine a controlled substance?

Regulatory status information explicitly identifies the active ingredient, Tetryzoline, as Not a controlled drug under the regulatory frameworks of the US Drug Enforcement Administration (DEA).


Q: Do I need a prescription to get Tyzine?

Official product forms and status confirm that Tetryzoline is classified and available as an Over-the-Counter (OTC) product.


Q: What should I do if I think I'm having a serious side effect from Tyzine?

Official labeling and safety guides emphasize that in the event of accidental ingestion or potential serious toxicity, the product information instructs individuals to immediately contact a Poison Control Center or seek emergency medical help. This instruction is given due to the documented risk of severe toxicity from high exposure.


Q: Can Tyzine affect my mood or mental health?

Regulatory documents list nervousness as a potential systemic effect of the medicine. Furthermore, official safety documents note that severe toxicity can potentially result in an altered mental state or irritability.


Q: What does 'contraindications' mean for Tyzine?

Contraindications is the term used in official labeling to define conditions or circumstances that explicitly prohibit the use of the medicine. For Tetryzoline, these include having narrow-angle glaucoma or co-administering with certain other medicines like MAOIs.


Q: Can Tyzine interact with herbal supplements like St. John's wort?

The official regulatory guidance states that a health professional should be consulted about all herbal products and supplements being taken. No specific restrictions on St. John's wort or other herbal supplements are documented in the mandatory labeling, but this general instruction suggests the need for awareness regarding potential combinations.


Q: Are there different strengths or doses of Tyzine?

Tetryzoline is approved and available in different concentrations, such as a 0.05% W/V solution. It is also formulated as separate products for its two approved routes of administration: a nasal solution and an ophthalmic (eye) solution.


Q: Why is Tyzine sometimes prescribed for condition Z?

Official documents list the medicine's indication as the temporary relief of congestion and redness. The regulatory label for Tetryzoline does not support or describe its use for any other specific condition outside of this official scope.


Q: How do doctors decide who can or cannot use Tyzine?

Official documents govern the decision-making process by outlining mandatory restrictions, known as contraindications (e.g., narrow-angle glaucoma or age under two), which prohibit use. Additionally, the label lists specific conditions, such as hypertension or severe cardiovascular disease, where caution is required during its use.


Q: Can I stop taking Tyzine suddenly?

The medicine is officially designated for short-term, as-needed relief only. Official guidance specifies that use is to be discontinued if the condition worsens or persists for more than 72 hours, which means the label accounts for the cessation of use as a normal part of the treatment guidelines.

How should Tyzine be stored and disposed of?

Storage Requirements

Tyzine (Tetryzoline) solutions must be stored at room temperature, generally between 15 C and 30 C (59 F and 86 F). The product must be kept away from excess heat, moisture, and direct light; it should not be stored in the bathroom. The container must be kept tightly closed when not in use. Any solution that has changed color or become cloudy must be discarded immediately.

Child Safety and Disposal

All Tyzine must be stored out of the sight and reach of children.

For disposal of unused or expired product, the official guidance recommends utilizing a drug take-back program. If a take-back program is unavailable, the solution must be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container, and placed in the household trash. The medication must not be poured down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tyzine found in:

A-Z Index: